{"id":17251,"date":"2023-12-11T19:54:45","date_gmt":"2023-12-11T18:54:45","guid":{"rendered":"https:\/\/www.hematostat.net\/?p=17251"},"modified":"2024-01-02T19:56:35","modified_gmt":"2024-01-02T18:56:35","slug":"la-commission-europeenne-approuve-elrexfio-de-pfizer-pour-le-myelome-multiple-en-rechute-et-refractaire","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/la-commission-europeenne-approuve-elrexfio-de-pfizer-pour-le-myelome-multiple-en-rechute-et-refractaire\/","title":{"rendered":"La Commission europ\u00e9enne approuve ELREXFIO\u00ae de Pfizer pour le my\u00e9lome multiple en rechute et r\u00e9fractaire"},"content":{"rendered":"<ul>\n<li>L&#8217;autorisation de mise sur le march\u00e9 conditionnelle est bas\u00e9e sur les r\u00e9sultats, issus de l&#8217;\u00e9tude de phase 2 MagnetisMM-3.<\/li>\n<li style=\"text-align: right;\">ELREXFIO est une immunoth\u00e9rapie dirig\u00e9e contre l&#8217;antig\u00e8ne de maturation des cellules\u00a0B et le r\u00e9cepteur CD3 des lymphocytes T pr\u00eat \u00e0 l&#8217;emploi, et administr\u00e9e par voie sous-cutan\u00e9e avec une fr\u00e9quence d&#8217;administration r\u00e9duite \u00e0 partir de la 25 \u00e8me semaine de traitement chez les patients r\u00e9pondeurs.<em>\n<p>D&#8217;apr\u00e8s un communiqu\u00e9 de presse de Pfizer le 11 d\u00e9cembre 2023.<\/em><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>L&#8217;autorisation de mise sur le march\u00e9 conditionnelle est bas\u00e9e sur les r\u00e9sultats, issus de l&#8217;\u00e9tude de phase 2 MagnetisMM-3. ELREXFIO est une immunoth\u00e9rapie dirig\u00e9e contre l&#8217;antig\u00e8ne de maturation des cellules\u00a0B [&hellip;]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[441],"class_list":["post-17251","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-admin6779"],"aioseo_notices":[],"authors":[{"term_id":441,"user_id":1,"is_guest":0,"slug":"admin6779","display_name":"HematoStat.net","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/4f64711e55fa3c9401676697c4783cec15305a6f940a0f120048b6141a611347?s=96&d=mm&r=g","first_name":"HematoStat.net","last_name":"","user_url":"http:\/\/www.hematostat.net","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/17251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=17251"}],"version-history":[{"count":1,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/17251\/revisions"}],"predecessor-version":[{"id":17253,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/17251\/revisions\/17253"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=17251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=17251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=17251"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=17251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}